"[I]t's not enough to offer an overpriced generic version of its own branded product," Weissman stated. "The company must roll back its unjustified and outrageous price increases."
On Monday, Mylan announced it would offer a generic version of its EpiPen after a week of controversy over skyrocketing drug prices. In 2009, the emergency injection cost $100 for a two-pack, but its cost has now reached $600. The generic version would cost $300.
Weissman added in his statement that Mylan's announcement simply allows the company to avoid admitting to price gouging for the life-saving device.
The example of Mylan's price manipulation is just an example of out-of-control drug pricing across the pharmaceutical industry in the United States, the statement concluded.